A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

NCT01468181 · Completed

Last updated 2026-05-28

This clinical trial tested the safety of the medication LY2189265 in Japanese adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 394 people

Who can join Ages 20+ · all sexes

Timeline Started 2011-11 · est. completion 2013-12

Where 14 sites · Japan

What this study is testing ClinicalTrials.gov NCT01468181 ↗

Description as written by the study sponsor.

This was a 52-week, multicenter, non-randomized, open-label, Phase 3 long-term safety study in participants with type 2 diabetes mellitus who have inadequate glycemic control with monotherapy of oral antihyperglycemic medication (OAM).

Treatments tested

LY2189265 also known as Dulaglutide Drug
Sulfonylureas (SU) Drug

SU is a pre-study prescribed dose and is not being provided as part of the trial.
Biguanides (BG) Drug

Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.
alpha-glucosidase inhibitor (a-GI) Drug

a-GI is a pre-study prescribed dose and is not being provided as part of the trial.
Thiazolidinedione (TZD) Drug

TZD is a pre-study prescribed dose and is not being provided as part of the trial.
Glinides Drug

Glinides is a pre-study prescribed dose and is not being provided as part of the trial.

Main thing measured	Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01468181 ↗